bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

KDDANet-a novel computational framework for systematic
uncovering hidden gene interactions underlying known drug-disease
associations
Hua Yu 1, #*, Lu Lu 2, #, Ming Chen 3, Hu Li 4, Chen Li 2,*, Jin Zhang 1, *
1

Center for Stem Cell and Regenerative Medicine & The First Affiliated Hospital, Department of
Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
2

Department of Human Genetics, Zhejiang University School of Medicine, Hangzhou, China.

3

College of Life Sciences, Zhejiang University, Hangzhou, China.

4

Center for Individualized Medicine, Department of Molecular Pharmacology & Experimental
Therapeutics, Mayo Clinic, Rochester, MN, USA.
#

These authors contributed equally.

*

Correspondence:yuhua200886@163.com, chenli2012@zju.edu.cn and zhgene@zju.edu.cn

Abstract
Inferring novel therapeutic indications of known drugs provides an effective method
for fast-speed and low-risk drug development and disease treatment. Various
computational tools have been developed to accurately predict potential associations
between drugs and diseases. Nevertheless, no method has been designed to unveil
pharmacological (toxicological) gene interactions underlying Known Drug-Disease
Associations (KDDAs). System-level interpretation and elucidation of molecular
mechanism underlying KDDAs remains a main challenge. Here, for the first time, we
presented a novel and general computational framework, called KDDANet, for
systematic uncovering hidden gene interactions underlying KDDAs from the
perspective of complex molecular network. KDDANet effectively implemented
minimum cost optimization and graph clustering on a unified flow network model.
The excellent performance and general applicability of KDDANet on uncovering
hidden genes underlying KDDAs were globally demonstrated by enrichment analysis
of known and novel KDDA genes against two well-curated databases across broad
types of diseases. Case studies on several types of diseases further highlighted that the
potential value of KDDANet on revealing hidden gene interactions underlying
1

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

KDDAs. Particularly, it‚Äôs worth noting that KDDANet can reveal the shared gene
interactions underlying multiple KDDAs. For facilitating biomedical researchers to
explore KDDA molecular mechanisms and guiding drug repurposing, we provided an
online web server, http://47.94.193.106/kdda/index, to browse, download and analyze
the predicted KDDA gene interactions. Our software and usage instruction were freely
available at https://github.com/huayu1111/KDDANet/.

2

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

1 Introduction
The conventional development of novel promising drugs for treating specific diseases
is a time-consuming and efforts-costing process, including discovery of new chemical
entities, target detection and verification, preclinical and clinical trials and so on
(Paul, et al., 2010). Compared with traditional drug development, computational drug
repositioning, i.e.predicting the novel indications of existing drugs, offers the
possibility for safer and faster drug development because of several steps of
tranditional drug development pipeline can be avoided during repurposing efforts
(Ashburn and Thor, 2004; von Eichborn, et al., 2011).Various computational tools,
including machine-learning and similarity-computation models, have been proposed
to predict novel associations between drugs and diseases for facilitating drug
repurposing (Iwata, et al., 2015; Lu and Yu, 2018). These methods can efficiently
exploit and integrate multi-level omic data sources for discovery of novel drug
indications and thus accelerating drug repositioning process. However, they seldomly
analyze the molecular mechanisms underlying Known Drug-Disease Associations
(KDDAs), which seriously hampered the development of drug repurposing and new
therapies.

Theoretically, drug repurposing has been proposed based on two molecular-level
facts. On one hand, complex diseases often involve multiple genetic and
environmental determinants, including multi-factor driven alterations and
dysregulation of a series of genes (Goh, et al., 2007). The dysfunction of these genes
will propagate and perturb certain biological processes by the interactions among
molecules, leading to the onset of diseases. On the other hand, one drug can exert
impacts on many targets and perturb multiple biological processes (Campillos, et al.,
2008; Yildirim, et al., 2007). As a result, the shared biological processes manifested in
certain disease state and induced by a known drug‚Äôs treatment suggest potential drug
repositioning. Therefore, developing the mechanism-oriented computational tools to
unveil these shared molecular interactions is of great significance for understanding
3

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

disease pathogenesis and guiding drug repurposing. However, few computational
tools have been developed to address this need from a perspective of complex
molecular network. To our knowledge, two types of methods have been intended to
identify drug-gene-disease co-modules. Kutalik et al. and Chen et al. developed PingPong Algorithm (PPA) and Sparse Network-regularized Partial Least Square (SNPLS)
to identify co-modules related to specific cancer cell lines of NCI-60 and CGP
projects, respectively (Chen and Zhang, 2016; Kutalik, et al., 2008). However, these
two methods need to integrate gene-expression and drug-response data of cancer cell
lines for constructing models and do not carry out prediction for other types of
diseases. The second type of method has been designed to study drugs and disease
with known related genes, including comCIPHER and DGPsubNet (Wang, et al.,
2014; Zhao and Li, 2012). The common shortcomings of these methods are the
identified co-modules including multiple drugs and diseases and thus did not uncover
molecular interactions bridging individual KDDA. Moreover, comCIPHER used only
1442 genes to construct learning model, its performance and generalization capability
cannot be accurately evaluated.

To fully understanding the molecular mechanism of individual KDDA and the shared
molecular processes among multiple KDDAs, it is essential to find routes to bridge
drug and its related disease and obtain a true picture of the roadmap of disease state
cellular responses with drug administration. To this end, we designed a novel and
general computational framework, called KDDANet, which used known interactome
network to identify molecular interactions underlying KDDAs, including components
that are otherwise hidden (Fig 1). KDDANet first built a unified flow model by
integrating drugs, genes and diseases into a heterogeneous network (Fig 1a). Then, the
minimum cost flow optimization, a classical algorithm which has been widely used in
previous studies (da Rocha, et al., 2016; Huang, et al., 2011; Yeger-Lotem, et al.,
2009), was designed and implemented to identify gene subnetwork bridging a given
query drug (disease) to its related diseases (drugs) (Fig 1b-c). Finally, Markov
4

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

CLustering (MCL) algorithm was adopted to uncover gene interaction modules
bridging the query drug (diseases) and each related disease (drug) (Fig 1d).

The key advantage (strength) of the KDDANet method was its ability to uncover the
hidden gene interactions and modules underlying KDDAs through implementing
minimum cost optimization and graph clustering on a unified flow network model.
Validation experiments against two gold standard databases, including DisGeNet
(http://www.disgenet.org/) (Pi√±ero, et al., 2016), and SMPDB (http://smpdb.ca/)
(Frolkis, et al., 2009) demonstrated that our method has the excellent performance for
uncovering known and novel genes bridging drugs (diseases) and their related
diseases (drugs). Case studies on several types of diseases further showed that the
potential value of our method on revealing hidden gene interactions of drug actions
for treating specific diseases. Particularly, our results demonstrated that KDDANet
can reveal the shared gene interactions underlying multiple KDDAs, which provided
more valuable guides for drug repurposing. In summary, we developed an effective
and universal computational tool for accurate and systematic uncovering molecular
modules underlying KDDAs and thus providing novel insights into the mechanism
basis of drug repurposing and disease treatments. The computed KDDA subnetworks
in this study were provided in an online web server at http://47.94.193.106/kdda/index
and the source code of KDDANet was freely available on
https://github.com/huayu1111/KDDANet/ for facilitating biomedical researchers to
explore KDDA molecular mechanisms and guiding drug repurposing.

5

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Fig 1. Schematic illustration of KDDANet computational framework. a) Mapping drugs and
diseases into the weighted gene network through known drug-target associations and gene-disease
associations. b) Constructing a unified flow network. c) Identifying the highest probability gene
sub-network connecting query drug and candidate diseases by minimum cost flow optimization
algorithm. d) Uncovering hidden gene interaction modules by Markov CLustering (MCL)
algorithm.

2 Materials and Methods
2.1 Datasets
6

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

The weighted human gene network, HumanNet, constructed by integrating multiple
data sources, was used in our current study (Cho, et al., 2016), in which the nodes
were represented by gene ID and connected by bidirectional edges. Drugs and targets
with known interactions were obtained from DrugBank database
(http://www.drugbank.ca/) on January 22, 2017. Currently, this database contained
9591 drug entries and 4661 non-redundant protein (i.e. drug target/enzyme/transporter
/carrier) sequences were linked to these entries. In this study, we selected 4861 drugs
with at least one known target which was contained in the weighted human gene
networks for further analysis. In total, 2196 known target proteins included in the
weighted human gene networks were connected to these drugs by 12014 interactions
(Dataset 1). Classification of diseases and disease-related genes were extracted from
the previous study (Goh, et al., 2007). We focused on 1441 diseases with at least one
related gene which was included in HumanNet for our study. In total, 16712
associations link these diseases to 1521 genes existing in HumanNet (Dataset 2). The
known drug-disease associations were extracted from Comparative Toxicogenomics
Database (Davis, et al., 2009) (Dataset 3). In this study, we focused only on 53124
associations in which the drug has at least one target gene and the disease has at least
one related gene contained in HumanNet. For simplicity and consistency, different
types of drug, disease and gene nomenclatures were converted to DrugBank drug ID,
OMIM disease ID and Entrez gene ID for subsequent modeling and analysis.

2.2 Construction of a unified flow network model
Our computational framework can be applied to two contexts: 1) uncovering hidden
gene interactions bridging a query drug and its related disease (SDrTDi); 2) unveiling
hidden gene interactions bridging a query disease and its related drug (SDiTDr). We
described below the construction process of unified flow network in the first context.
Overall, the unified flow network model was built by integrating the query drug and
all its related diseases into the weighted gene network based upon known drug-target
relations and gene-disease associations (Fig.1A). For the given query drug, we used it
7

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

as source node (S) and integrated it into gene network by introducing the directed
edges from it point to its target genes. For each its related disease, we mapped the
disease to gene network by introducing the directed edges from its related genes point
to it. To obtain a flow network, we incorporated a sink node T and introduced a
directed edge pointing from each disease to it.

In the integrated heterogeneous network, we assigned each edge a weight value
reflecting the probability that two nodes were associated. For the edges linking two
genes, their weight values were directly extracted from original literature (Cho, et al.,
2016). Since there was not reliable probability knowledge available between different
types of nodes (i.e. drug, gene and disease), the weighting scheme was simply
designed as follow.
I) For each edge connecting the query drug (S) and its target gene v or linking a gene
g and each its related disease d, we given it a weight wSv = 1 or wgd = 1.
II) For each edge linking each disease d to sink node T, we assigned it a weight wdT =
1.

We further defined for each edge in this heterogeneous network a capacity value that
limits the flow. For each edge connecting the query drug S to its target gene v or
linking the disease d to sink node T, we assigned it a capacity cSv or cdT that equal
positive infinity allowing unlimited flow quantity. For other edges, we assigned them
a capacity cij = 1. With these deÔ¨Ånitions, a unified flow network was constructed as a
complex heterogeneous graph G = (V, E), where V was the set of vertices and E was
the set of edges. This graph included two types of edges (bidirectional and directed)
and three types of nodes (drugs, genes and diseases). Each edge was assigned with a
weight and a capacity. To apply our computational framework in the second context,
the query disease and a set of its related drugs need to be mapped into gene network
by disease-related genes and drug‚Äôs target genes. After this, the weights and capacities
of network edges can be set using the same method as above for constructing the
8

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

unified Ô¨Çow network model.

2.3 Minimum cost flow optimization and Markov CLustering (MCL)
The main aim of this study was to identify hidden gene interactions relating a query
drug (disease) and its related diseases (drugs). This first step to solve this problem
was that finding a highest probability sub-network that can connect a query drug
(disease) to each its related disease (drug). This requirement could be solved using
‚Äúflow algorithm‚Äù, a type of computational approach that has been employed in our
previous study and other labs to predict the disease-related genes and uncovering
unknown biological pathways (Chen, et al., 2011; Dasika, et al., 2006; Huang, et al.,
2011; Yeger-Lotem, et al., 2009; Yu, et al., 2017).

As mentioned in 2.2 Section, our method can be applied in two contexts by simply
reconstructing flow network model, we described below our algorithm in the context
of uncovering hidden gene interactions bridging a query drug and its related diseases.
Since we want to find the topological structure of hidden gene interactions associating
a query drug with a series of its related diseases, we required that flow pass from the
query drug through gene network to its related diseases. We formulated our goal as a
minimum cost flow optimization problem (Huang, et al., 2011; Yeger-Lotem, et al.,
2009) (Fig.1B). Given the unified flow network, this problem can be expressed as a
linear programming formula that minimized the total cost of the flow network while
diffusing the most flow from source node to sink node. Let wij, fij and cij referred to the
weight, flow and capacity from node i to node j, respectively. The linear programming
formula can be written as follow.
Minimize

‚àëùëñ‚ààùëâ,ùëó‚ààùëâ(‚àí log(ùë§ùëñùëó ) ‚àó ùëìùëñùëó ) ‚àí (ùõæ ‚àó ‚àë ùëìùëÜùë£ )

(1)

Subject to

‚àëùëó‚ààùëâ ùëìùëñùëó ‚àí ‚àëùëó‚ààùëâ ùëìùëóùëñ ‚àÄùëñ ‚àà ùëâ ‚àí {ùëÜ, ùëá}

(2)

ùëìùëÜùë£ ‚àí ‚àëùëñ‚ààùê∑ ùëìùëñùëá = 0

(3)

0 ‚â§ ùëìùëñùëó ‚â§ ùëêùëñùëó

(4)

Where V denoted a set of nodes included in the flow network; S denoted the source
9

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

node (the query drug) and v denoted it target gene. The parameter gamma (ùõæ) controls
the size and the quality of the optimized sub-network. The first component of this
formula, ‚àëùëñ‚ààùëâ,ùëó‚ààùëâ(‚àí log(ùë§ùëñùëó ) ‚àó ùëìùëñùëó ), ensured minimizing the network cost that given
priority to obtain higher probability gene interactions, at the same time, the second
component, ‚àí(ùõæ ‚àó ‚àë ùëìùëÜùë£ ), indicated maximizing the total flow across entire network.
Expression (2) guaranteed the conservation of flow quantity for each node in the gene
network. Expression (3) ensured that all flow out of the source node must arrive at the
sink node. Expression (4) guaranteed that the flow via each edge is non-negative and
does not exceed its capacity. This optimization problem can be efficiently solved
using primal simplex method provided in Mixed Integer Linear Programming (MILP)
solver (http://lpsolve.sourceforge.net/). The solution
ùëéùëüùëîùëöùëñùëõùëìùëñùëó > 0 ‚àëùëñ‚ààùëâ,ùëó‚ààùëâ(‚àí log(ùë§ùëñùëó ) ‚àó ùëìùëñùëó ) ‚àí (ùõæ ‚àó ‚àë ùëìùëÜùë£ ) got the highest probability
sub-network relating the query drug with all its related diseases. For each related
disease of query drug, we searched the all possible paths linking query drug to it and
used genes contained in these paths to obtain subnetwork bridging query drug and this
disease. Once the subnetwork underlying query drug and each its related disease was
identified, Markov Clustering (MCL) algorithm (https://micans.org/mcl/) can be
adopted to discover hidden gene interaction modules by using the flow quantities
through edges of subnetwork as weight values.

2.5 Performance evaluation
In most of cases, the true gene interactions underlying KDDAs were poorly
understood. Consequently, there was no perfect way to assess the prediction results.
Here, we systematically evaluated the performance of KDDANet based on fold
enrichment of true genes underlying KDDAs against random genome background
(full network). The fold of enrichment was calculated by the following formula:
ùëù
ùëÄ
√ó
ùëû
ùëÅ

(1)

where, p was the number of true positive genes underlying a KDDA; q was the
10

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

number of inferred genes in the resulting subnetwork; M denoted the number of true
positive genes in the gold standards and N represented the number of all genes in full
network.

Using this method, we conducted two main evaluation experiments: I) Uncovering
known genes which directly linked by query drug and it related disease in the unified
flow network model; II) Uncovering novel genes which have not directly connected
by query drug and its related disease in the unified flow network model, but were to
be shared between disease-related genes and drug-related genes. To achieve the
second, we collected a comprehensive knowledgebase of recently updated known
disease-related genes and known drug-related genes as gold standards. The known
disease-related genes were directly downloaded from DisGeNet database, a largest
publicly available collections of genes and variants associated to human diseases
(Pi√±ero, et al., 2016), which contained 130097 associations between 14345 genes and
5391 diseases (Dataset 4). We obtained known drug-related genes by drug-pathway
associations extracted from SMPDB, a well-established small molecule pathway
database (Frolkis, et al., 2009; Jewison, et al., 2014). If a pathway was associated with
a drug, we considered that all genes in this pathway were associated with this drug.
This resulted in 15835 associations connecting 598 drugs and 810 genes (Dataset 5).
The network visualization was carried out using Cytoscape (https://cytoscape.org/).
KEGG pathway enrichment analysis was performed by clusterProfiler R package (Yu,
et al., 2012).

3. Results
3.1 Excellent performance and general applicability of KDDANet computational
framework
We first asked whether the true genes underlying Known Drug-Disease Associations
(KDDAs) have been found in previous biomedical researches by checking the
discrepancy between Known Drug Target Genes (KDTGs) and Known Disease
11

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Related Genes (KDRGs). To evaluate the discrepancy between KDTGs and KDRGs,
we collected the KDTGs and KDRGs of 4861 drugs and 1441 diseases from the
recently updated data source of DrugBank and DisGeNet database, respectively. Then,
we analyzed the overlap ratio between KDTGs and KDRGs underlying 53124
KDDAs obtained from Comparative Toxicogenomics Database (CTD) (Davis, et al.,
2009). We observed that the most gene sets demonstrated extremely low overlap ratio,
with the increasing of gene number, the overlap ratio was sharply decreased (Fig 2a).
We further checked the overlap percentage in different types of diseases and found the
overlaps between KDTGs and KDRGs were all small for 19 disease types (Fig 2b).
This discrepancy between KDTGs and KDRGs indicated that each gene set alone
provides only a limited and biased view of KDDAs. Meanwhile, these outcomes also
suggest that the current biomedical researches in drug development are not in well
conjunction with disease pathogenesis research across broad types of diseases. To
address this, we designed a novel computational framework, KDDANet, which
effectively integrated network flow optimization and graph clustering analysis to
bridge this gap (Fig.1, see Methods for details).

To comprehensively evaluate the capability of KDDANet framework on uncovering
the hidden genes underlying KDDAs, we first checked whether the KDTGs and
KDRGs were contained in the resulting subnetworks by performing enrichment
analysis with a range of ùõæ settings from 4 to 12 with a step of 1 (see Methods for
details). For comparing with background enrichment, we carried out a permutation
test by producing random subnetworks with the same number of genes. We found
that, in SDrTDi and SDiTDr contexts, the KDTGs and KDRGs were significantly
enriched in the resulting subnetworks against random subnetworks (Fig S1a-d). This
indicated that KDDANet can effectively capture the genes associated with query
drugs (diseases) and their related diseases (drugs). To check whether the known true
KDDA genes used to construct network flow model were captured in our prediction
results, we then performed the enrichment analysis of shared genes between KDTGs
12

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

and KDRGs underlying the same KDDAs (see Methods for details). As shown in Fig
2c and 2d, we can observe that, in SDrTDi and SDiTDr contexts, the subnetworks
outputted by KDDANet have obviously higher enrichment of the shared genes when
compared with random permutation subnetwork. For further demonstrating whether
our computational framework can uncover novel true KDDA genes which were not be
shared between KDTGs and KDRGs, we collected a set of novel shared genes
between drug related genes and disease related genes from recently updated SMPDB
and DisGeNet database, respectively. We performed enrichment analysis and found
that the resulting subnetworks have still prominently higher enrichment of these novel
shared genes than random permutation subnetwork. Get together; these results
suggested that our model was a powerful tool for achieving the goal of systematic
uncovering hidden genes underlying KDDAs.

As the size and quality of KDDANet output subnetwork depended on a parameter ùõæ.
Higher ùõæ values will identify more links between the source node and the sink node
but with lower confidence. To obtain suitable values for ùõæ, we run KDDANet with ùõæ
values ranging between 4 and 12 with a step of 1. For each of the output subnetwork,
we computed the percentage of input, namely KDTGs and KDRGs, that were
incorporated into the network, as well as the percentage of low probability edges with
weight smaller than 0.3. As shown in Fig S1e and Fig S1f, we observed that the
percentages for KDTGs, KDRGs and low probability edges contained in resulting
subnetworks became stable when Œ≥ = 6 and 8 for SDrTDi and SDiTDr, respectively.
We therefore selected Œ≥ = 6 for SDrTDi and Œ≥ = 8 for SDiTDr as they were the
minimal values with which a significant fraction of the input was incorporated while
the percentage of low probability edges remained small in respective contexts. After
confirming the excellent performance and obtaining the optimal Œ≥ value of KDDANet
framework by global and systematic analysis, we further determined whether
KDDANet has the general application value across a variety of disease types. Using
the same enrichment analysis strategy on 19 different types of diseases, we found that
13

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

KDDANet can make effective capturing of true genes underlying KDDAs for all 19
types of diseases (Fig 2g-h and Fig S1g-h, Dataset 6 and Dataset 7). Collectively,
these results indicated that KDDANet was an excellent and general computational
tool which can be applied to uncover hidden genes underlying KDDAs across broad
types of diseases.

Fig 2. Excellent performance and general applicability of KDDANet method. a) Scatter plot
demonstrated the distribution of overlap ratio between KDTGs and KDRGs underlying the same
14

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

KDDAs; The x-axis denoted the total number of KDTGs and KDRGs underlying the same
KDDAs. b) Colored scatter plot demonstrated the Minimum (Min), 25th Quantile (Q1), 50th
Quantile (Q2), 75th Quantile (Q3) and Maximum (Max) of overlap ratio distribution in different
types of diseases; The size and color of point denoted the gene number and overlap ratio,
respectively; c) Violin plot demonstrated the enrichment of known shared genes between KDTGs
and KDRGs underlying same KDDAs with different ùõæ settings in SDrTDi context, using random
permutation as control (Rd); d) Similar to c) demonstrating the enrichment of known shared genes
in SDiTDr context; e) Similar to c), demonstrating the enrichment of novel shared genes between
drug related genes collected from SMPDB database and disease related genes obtained from
DisGeNet database; f) Similar to d), demonstrating novel shared genes between drug related genes
collected from SMPDB database and disease related genes obtained from DisGeNet database; g)
Violin plot demonstrated the enrichment of known shared genes between KDTGs and KDRGs
underlying the same KDDAs across different types of diseases in SDrTDi context; Values in
parentheses denoted the number of KDDAs. h) Similar to g), demonstrating the enrichment of
known shared genes between KDTGs and KDRGs in SDiTDr context.

3.2 Global functional analysis and detailed case studies highlight that the
potential value of KDDANet for revealing hidden gene interactions underlying
individual KDDA
The comprehensive analysis above demonstrated that KDDANet was powerful for
predicting the possible gene links underlying KDDAs. Here, we further evaluated the
rationality of functions of the KDDA gene interaction subnetworks by carrying out a
global enrichment of all predicted KDDA subnetworks against 53 classical KEGG
pathways. We calculated Enrichment Score (ES) for each pathway in all 19 types of
diseases (Fig S2). The obtained enrichment results can be validated by existing
scientific knowledge. For example, we observed that p53 signaling pathway has
relative higher ES value in cancer when comparing with other pathways for both
SDrTDi and SDiTDr resulting modules (see Fig S2). For neurological disease, we
found that the notch signaling pathway was significantly enriched in both SDrTDi and
15

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

SDiTDr resulting modules (Fig S2). This was consistent with the previous discoveries
that demonstrated the association of notch-related pathways with neurological
disorders and the potential of agents target notch signaling as therapeutic
interventions for several different central nervous system disorders (Lathia, et al.,
2008). Interestingly, we found that ophthamological, immunological, endocrine,
developmental and cardiovascular diseases have consistent less enrichment on all 53
known KEGG pathways than other types of diseases (Fig S2). This indicated that the
known drugs developed to cure these types of diseases cannot be well explained by
these known pathways and the uncovered molecular interactions underlying KDDAs
in these types of diseases is great value for further experimental studies.

In addition to global function analysis KDDA genes, we performed the detailed case
studies to further demonstrate the potential merits of KDDANet for uncovering gene
interactions underlying individual KDDA. For simplicity, we randomly selected the
predicted subnetworks of 4 KDDAs including DB00489 (sotalol)-176807 (prostate
cancer) association, DB01109 (heparin)-601665 (obesity) association, DB03147
(flavin adenine dinucleotide)-114480 (breast cancer) association and DB01022
(phylloquinone)-104300 (Alzheimer disease) association for detailed analysis. Sotalol
was normally used to treat life threatening ventricular arrhytmias and maintained
normal sinus rhythm in patients with atrial fibrillation. It has been reported that sotalol
was associated with decreased prostate cancer risk (Kaapu, et al., 2015). For sotalolprostate cancer association, we predicted a subnetwork consisting of 31 genes and 28
links (Fig 3a). All three known target genes, KCNH2, ADRB1 and ADRB2, were
included in this subnetwork. Meanwhile, this subnetwork also captured 12 diseaserelated genes. Among genes included in this subnetwork, KCNH2, PRKACA and
PRKAR1A were the novel shared genes between recently updated drug-related genes
and disease-related genes, which were not used as KDTGs and KDRGs in our flow
network model. The top 10 enriched KEGG terms were demonstrated in Fig 3b. As
expected, PI3K-Akt signaling pathway, MAPK signaling pathway and FoxO signaling
16

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

pathway were the classic signaling pathways related to cancer formation and
development. The associations between EGFR tyrosine kinase inhibitor resistance,
Relaxin signaling pathway, AGE-RAGE signaling pathway and prostate cancer have
also been widely investigated and reported in the previous works (Bao, et al., 2015;
Neschadim, et al., 2015; Ozvegy-Laczka, et al., 2005). Moreover, autophagy and focal
adhesion were two widely observed biological processes in cancer (Eke and Cordes,
2015; Farrow, et al., 2014). By applying MCL with default parameters, this
subnetwork was further decomposed into 3 gene modules, M1, M2 and M3.
Obviously, the enriched KEGG terms of M1 and M3 were closely related to cancer
formation and development (Fig 3c). Surprisingly, M2 was not enriched to any KEGG
term, indicating that it might be a novel module explaining this association. DB01022
(phylloquinone)-104300 (Alzheimer disease) association has been reported in
previous studies (Alisi, et al., 2019). A subnetwork including 46 genes and 44 links
were uncovered for this association (Fig 3d). All two known target genes of
phylloquinone and 18 Alzheimer disease related genes were identified in this
subnetwork. Interestingly, for this association, two separated gene modules were
detected by two known targets of phylloquinone. The enriched KEGG terms of these
two gene modules demonstrated strong closeness with Alzheimer disease (Fig 3e-f).

The association between DB01109 (heparin) and 601665 (obesity) was inferred by
multiple genes as described in CTD database. For this association, KDDANet
predicted a subnetwork containing 168 edges connecting 169 genes (Fig S3a). We
found that all 3 known drug target genes and 67 disease-related genes were captured
in this subnetwork. Particularly, 9 genes were the novel shared genes between recently
updated drug-related genes and disease-related genes which were not used as KDTGs
and KDRGs in our flow network model. Interestingly, 3 genes used to infer this
KDDA, including ARK1, PARP1 and TNF, were also effectively captured in the
resulting subnetwork. The top 10 enriched functions of this subnetwork were
demonstrated in Fig S3b. As expected, Insulin resistance, Type II diabetes mellitus,
17

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Insulin signaling pathway and Adipocytokine signaling pathway were the frequently
reported molecular processes associated with obesity (Kahn and Flier, 2000; Taylor
and Macqueen, 2010). In addition, Proteoglycans, Lipolysis and AMPK signaling
pathway were also highly correlated with Insulin resistance (Langin, et al., 2005;
Olsson, et al., 2001; Viollet, et al., 2009). For some KEGG terms, though we did not
observe their associations with obesity, they might be the true biological processes
underlying this association. We delineated this subnetwork into gene modules. The
top 3 gene modules and their enriched functions were demonstrated in Fig S3a and
Fig S3c. The major enriched functions of these modules were related to obesity. For
DB03147 (flavin adenine dinucleotide)-114480 (breast cancer) association, we
obtained a subnetwork consisting of 148 genes and 137 interactions (Fig S3d). As
expected, CAT, a gene used to infer this association, was included in this subnetwork.
In consistent with this, among 86 targets of DB03147, 25 were contained in this
subnetwork. Meanwhile, 44 breast cancer related genes were also captured in this
subnetwork. Further analysis demonstrated that the mainly enriched functions of this
subnetwork and inferred gene modules were closely related to cellular basis of breast
cancer (Fig S3e-f). All these results above indicated that the molecular basis of
KDDAs can be revealed by our proposed approach.

18

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Fig 3. Case studies on DB00489 (Flavin adenine dinucleotide)-176807 (Prostate Cancer)
association and DB01022 (Phylloquinone)-104300 (Alzheimer disease) association. a)
Uncovered gene interaction subnetwork for DB00489-176807 association in SDrTDi context; b)
Top 10 enriched KEGG terms of subnetwork genes underlying DB00489-176807 association; c)
Representatively enriched KEGG terms of 3 identified gene modules underlying DB0048919

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

176807 association; d) Uncovered gene interaction subnetwork underlying DB01022-104300
association in SDrTDi context; e) Enriched KEGG terms of subnetwork genes underlying
DB01022-104300 association; f) Representatively Enriched KEGG terms of two uncovered gene
modules underlying DB01022-104300 association.

3.3 KDDANet uncovers the shared gene interactions underlying multiple KDDAs
Analysis on above fully demonstrated that KDDANet can uncover hidden gene
interactions underlying individual KDDA. Here, we further asked whether KDDANet
can reveal the shared gene interactions underlying multiple KDDAs. We answered
this from two aspects: I) Multiple Diseases associating with One Drug (MDiODr); II)
Multiple Drugs associating with One Disease (MDrODi). Considering the practical
merits of first one analysis, we required multiple diseases belongs to same type of
diseases. To perform these two evaluations, we produced meta-subnetworks by
combining multiple KDDA subnetworks for 12386 MDiODr combinations and 773
MDrODi combinations produced in SDrTDi context. The weight of an edge in the
meta-subnetwork was defined as the number of KDDA subnetworks containing this
edge divided by the total number of KDDA subnetworks. The higher weight value of
a link in meta-subnetwork indicated more conservation and commonality. Thus, we
used the weight value to evaluate the capacity of KDDANet in unveiling the shared
gene interactions underlying multiple KDDAs. We carried out a permutation test by
producing random meta-subnetworks with the same number of edges for comparing
with random background. As shown in Fig 4a-d, the weights of KDDANet metasubnetworks were significantly higher than random meta-subnetworks across different
types of diseases. This indicated the gene interactions tend to be shared in KDDANet
meta-subnetworks than random background. We also conducted the same analysis in
SDiTDr context for 12189 MDiODr combinations and 773 MDrODi combinations
and obtained the similar results (Fig S4a-d). All these results indicated that KDDANet
can effectively uncover the shared gene interactions underlying multiple KDDAs.

20

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Next, we presented some examples for intuitively describing the capability of
KDDANet in identifying shared gene interactions underlying multiple KDDAs. For
MDiODr, we selected two cases: I) DB00370 (mirtazapine)-cancer associations and
II) DB00392 (profenamine)-neurological diseases associations, for detailed
descriptions. Considering the biomedical significance and conciseness, we selected
the edges of meta-subnetwork with weights larger than 0.6 for presentation. As
recorded in CTD database, mirtazapine was associated with 9 cancers, including
Colorectal Neoplasms, Breast Neoplasms, Neuroblastoma, Glioma, Urinary Bladder
Neoplasms, Stomach Neoplasms, Esophageal Neoplasms, Lung Neoplasms and
Prostatic Neoplasms. Fig 4e showed the shared meta-subnetwork including 25 genes
and 24 edges. Among these genes, HTR2C, ADRA2A, OPRK1 and HRH1 were
mirtazapine‚Äôs target genes and TP53, BRAF, KRAS and EGFR were cancer related
genes. A KEGG term enrichment demonstrated that these genes play roles in various
cancers, including 4 cancers associated with mirtazapine as described on above (Fig
4f). Consistent with this, the enriched pathways, such as Sphingolipid signaling
pathway, were closely related to cancer formation and development (Ogretmen,
2018). As reported in CTD database, profenamine has associations with three
neurological diseases, including Parkinsonian Disorders, Multiple Sclerosis and
Alzheimer Disease. The shared meta-subnetwork contained 10 edges linking 13 genes
with 3 profenamine‚Äôs target genes, CHRM1, CHRM2 and GRIN3A (Fig 4g). The top
10 enriched KEGG terms were demonstrated in Fig 4h. A majority of enriched KEGG
terms, such as Cholinergic synapse and Glutamatergic synapses, have been reported
dysfunction in neurological disorders and diseases (Moretto, et al., 2018; Tata, et al.,
2014)

For MDrODi, we observed that the shared gene interactions were significant less than
MDiODr (Fig 4a-d and Fig S4a-d). Nevertheless, we also observed some interesting
cases. For example, GRACILE syndrome, a metabolic disease, was associated with
13 drugs as recorded in CTD database. A shared meta-subnetwork including 9 genes
21

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

and 8 edges were obtained for this disease (Fig S4e). This meta-subnetwork contained
6 genes which were known related to this disease. All 9 genes in this subnetwork were
involved in Oxidative phosphorylation. This was expected as GRACILE syndrome
was a fatal inherited disorder caused by a mutation in an oxidative phosphorylation
related gene, BCS1L, necessary for providing cells with energy. Another example was
the Keratoconus, an ophthamological disease, was associated with 3 drugs,
acetaminophen, valproic acid and theophylline. Keratoconus and these drugs shared a
meta-subnetwork consisting 15 genes and 11 edges (Fig S4f). This meta-subnetwork
included 5 Keratoconus related genes, i.e., PIKFYVE, TACSTD2, TGFBI, KERA and
COL8A2, and both valproic acid and theophylline‚Äôs target gene, HDAC2. It is also
expected that SNW1 and HDAC2 were contained in this meta-subnetwork as they
were involved in notch signaling pathway which is down-regulated in keratoconus
(You, et al., 2018). Interestingly, consistent with the associations between collagen
genes and keratoconus (Bykhovskaya, et al., 2016), a novel collagens coding gene,
COL1A1, was captured in this meta-subnetwork. Taken together, these shared gene
interactions provided more valuable and general guides for drug repositioning and
disease treatment as they characterized the common molecular mechanism among
multiple KDDAs.

22

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Fig 4. KDDANet uncovered the shared gene interactions underlying multiple KDDAs.
a) Violin plot demonstrates the distributions of weight values in KDDANet meta-subnetwork and
random meta-subnetwork for MDiODr in SDrTDi context. b) Violin plot demonstrates the
23

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

distributions of weight values in KDDANet meta-subnetwork and random meta-subnetwork for
MDrODi in SDrTDi context. c) Violin plot demonstrates the distributions of weight values in
KDDANet meta-subnetwork and random meta-subnetwork for MDiODr in SDrTDi context across
different types of diseases; d) Violin plot demonstrates the distributions of weight values in
KDDANet meta-subnetwork and random meta-subnetwork for MDrODi in SDrTDi context across
different types of diseases; e) Uncovered gene interaction subnetwork for DB00370 -cancer
associations in SDrTDi context; f) Top 10 enriched KEGG terms of shared meta-subnetwork
genes underlying DB00370-cancer association; g) Uncovered gene interaction subnetwork for
DB00392-neurological diseases associations in SDrTDi context; h) Top 10 enriched KEGG terms
of shared meta-subnetwork genes underlying DB00392-neurological diseases associations.

3.4 A web server for querying and browsing gene interactions underlying
KDDAs
To help biomedical researchers to understand the pathogenesis of disease and promote
drug development, we developed an online web server,
http://47.94.193.106/kdda/subnet, for facilitating the researchers to browsing and
analyzing hidden gene interactions underlying KDDAs. Our website was divided into
3 parts (Fig 5a): I) querying and browsing gene interactions underlying individual
KDDA (iKDDA); II) querying and browsing shared gene interactions underlying
multiple KDDAs connecting multiple diseases to one drug (MDiODr) and III)
querying and browsing shared gene interactions underlying multiple KDDAs
connecting multiple drugs to one disease (MDrODi). For Part I, hidden gene
interactions underlying 52878 and 51745 KDDAs for SDrTDi and SDiTDr were
provided for visualizing and downloading, respectively (Fig 5b). Users can input a
query DrugBank drug id or drug name and its associated OMIM disease id or disease
name. When users selected the corresponding optimization context (SDrTDi or
SDiTDr) and clicked the search button, the subnetwork underlying this KDDA was
displayed on a panel. In the panel, the size of node was proportional to the node
degree, the thickness of edge denoted the flow quantity and the known drug target
24

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

genes and disease related genes were filled with different colors. Users can click any
gene node to skip the NCBI Gene website to learn about the knowledge of this gene.
The content of subnetwork underlying this KDDA can directly be downloaded for
performing downstream analysis, such as module identification and function analysis.

For Part II, 12386 and 12189 shared meta-subnetworks were contained in our web
server for SDrTDi and SDiTDr, respectively. When user input the query drug and
disease type, all its associated diseases under this disease type and the shared metasubnetwork were instantly visualized. User can click any related disease to link to
OMIM database for acquainting disease related knowledge. To facilitate visualizing
and browsing, we selected edges with weight larger than 0.1 for displaying. The
weight of interaction of meta-subnetwork was characterized by thickness of edge.
Similar to Part I, drug target genes and disease-related genes were displayed with
different colors. Any genes in the shared meta-subnetwork can be clicked to link to
NCBI Gene website for obtaining related information. The shared meta-subnetwork
can be also downloaded for user specific downstream analysis. (Fig 5d). For Part III,
773 shared gene interaction meta-subnetworks were contained in our web server (Fig
5c). The functions of this part were similar to Part II. Finally, we designed a bulk
download interface for facilitating user to obtain all subnetworks mentioned above.
Overall, we provided a simply and easy-to-use web server for exploring the molecular
mechanism underlying KDDAs and thus help researchers to understand the
pathogenesis of disease, accelerate drug repurposing and disease treatment.

25

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Fig 5. An online web server for visualizing gene interactions underlying KDDAs. a) Home
page of our web server; b) Web page for visualizing hidden gene interaction subnetwork for
iKDDA; c) Web page for visualizing the shared meta-subnetwork for MDiODr; d) Web page for
visualizing the shared meta-subnetwork for MDrODI.

26

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

4. Discussion
For drug repurposing, various computational methods have been developed to infer
novel drug-disease associations (Iwata, et al., 2015; Lu and Yu, 2018). However, the
molecular mechanisms underlying KDDAs have been still not well explored. This
was confirmed by the extremely low overlap ratio between KDTGs and KDRGs. The
discordance between KDTGs and KDRGs also suggested the existence of hidden
gene interactions underlying KDDAs. Therefore, uncovering the hidden gene
interactions underlying KDDAs became an important scientific problem for guide
drug repurposing. Minimum cost network flow optimization is a classical graph
theory algorithm, has been adopted to uncover unknown molecular processes of cell
responses to biotic/abiotic stresses and candidate disease genes (Huang, et al., 2011;
Yeger-Lotem, et al., 2009). It is worth mentioned that Hu Li, Ph.D., and his research
team developed a cutting-edge method, called NetDecoder, which used minimum cost
network flow optimization to dissect context-specific biological subnetwork (da
Rocha, et al., 2016). This method enables researchers to uncover context-dependent
drug targets, which has considerable application value for personalized medicine. The
successful practices of minimum cost network flow optimization in these studies
implicated that it is helpful in biological and medical researches. Inspired by these
works, we integrated minimum cost network flow optimization and graph clustering
algorithm and developed a novel computational framework, called KDDANet, to
reveal the hidden gene interactions and modules underlying KDDAs. KDDANet
allowed for a global and systematic exploration the molecular mechanisms underlying
known drug-disease associations, which can effectively complement to the existing
computational methods for novel drug-disease association prediction, for example, a
published method in our previous study (Lu and Yu, 2018). We applied KDDANet to
systematically unravel the hidden gene interactions underlying 53124 KDDAs. For
SDrTDi and SDiTDr context, the enrichment results of known and novel KDDA
genes of 52878 and 51745 KDDA subnetworks fully demonstrated the powerful
prediction ability and general applicability of our computational framework. In order
27

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

to intuitively demonstrate that gene interactions identified by KDDANet were highly
reliable and useful, we conducted global KEGG pathway enrichment analysis and
detailed case studies to further illustrate this. An important capability of KDDANet
method was that it can reveal the shared gene interaction underlying multiple KDDAs
as showed in our results. This can provide more valuable guides for drug
repositioning and disease treatment as the shared gene interactions were closely
related to the molecular basis of drug repurposing.

As described in Results section, the global gene interaction roadmaps obtained by
KDDANet demonstrated the power of integrative approaches to illuminate
underexplored molecular processes underlying KDDAs. However, there are some
limitations that influence the KDDANet application in precision medicine and
personalized care. Firstly, the gene interactome network used in our flow network
model was static and did not capture network rewiring events under different
circumstances. Indeed, the true biological network are highly dynamic and undergo
continuous rewiring events (da Rocha, et al., 2016). For a KDDA in specific context,
constructing a context-specific interactome network might be more appropriate for
accurate uncovering hidden KDDA gene interactions. Secondly, the used gene
interactome did not contain enough information of gene interaction. In further studies,
we will integrate other non-coding genome elements, especially long non-coding
RNA and microRNA for constructing a comprehensive gene interactome network in a
context-dependent method. In addition, integrating biological networks from other
omics layers, such as epigenetics, can further enhance the accuracy of KDDANet in
discovering KDDA subnetworks and the associated key genes and thus help us better
understand KDDA at multi-omics levels. Indeed, the ability of KDDANet to analyze
large-scale heterogeneous interactome data containing tens of thousands of nodes and
edges make it can well be suited to analyzing the accumulating data from ‚Äòmultiomics‚Äô technologies and biomedical research. Thirdly, KDDANet cannot carry out
prediction for drug-disease associations when a drug‚Äôs target genes were unknown or
28

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

when a disease has not been related to a set of genes. For this, we plan to calculate the
similarity scores between drugs and the similarity scores between diseases, and then
integrate drugs without any target genes and diseases without any related genes to our
flow network model by similarity scores. Finally, due to the limitations of current
experimental conditions, we were not able to do wet experiments to verify the
predictions. Once the experimental conditions allowed, we will focus on some
specific diseases and conducted molecular experiments, such as pooled CRISPR
screen combined with single cell transcriptome sequencing, to systematically verify
the predicted KDDA gene interactions.

In summary, we presented a novel network-based computational framework that has
broad utility and application value in biomedical studies. Our method allowed the
researchers to explore hidden gene interactions underlying KDDAs. Although some
challenges are still existing for enhancing the prediction accuracy of our method, the
inferred KDDA subnetworks and related genes discovered can serve as roadmaps for
guiding drug repurposing and disease treatment. Insights learned from our predicted
subnetworks will enable to help researchers to design novel drugs to reverse disease
phenotypes via targeting hub genes in the KDDA subnetwork. For helping drug
repurposing in wet lab, we provided an online web server to facilitate researchers to
browse and analyze the predicted KDDA gene interaction subnetworks. Our online
web server was flexible allowing researchers to query and visualize the predicted
subnetwork for KDDAs consist of several thousands of drugs and several hundreds of
diseases extracted from CTD database. As the huge amount of biological data was
becoming available in the biomedical study, we believed that the predictions of
KDDANet could be more reliable and useful.

29

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

References
Alisi, L., et al. (2019) The Relationships Between Vitamin K and Cognition: A Review of Current
Evidence, Frontiers in Neurology, 10, 239.
Ashburn, T.T. and Thor, K.B. (2004) Drug repositioning: Identifying and developing new uses for
existing drugs, Nature Reviews Drug Discovery, 3, 673-683.
Bao, J.M., et al. (2015) AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by
promoting Rb phosphorylation and degradation, American Journal of Cancer Research, 5, 1741-1750.
Bykhovskaya, Y., Margines, B. and Rabinowitz, Y.S. (2016) Genetics in Keratoconus: where are we?,
Eye and Vision, 3, 16.
Campillos, M., et al. (2008) Drug target identification using side-effect similarity, Science, 321, 263266.
Chen, J. and Zhang, S. (2016) Integrative analysis for identifying joint modular patterns of geneexpression and drug-response data, Bioinformatics, 32, 1724-1732.
Chen, Y., Jiang, T. and Jiang, R. (2011) Uncover disease genes by maximizing information flow in the
phenome-interactome network, Bioinformatics, 27, i167.
Cho, A., et al. (2016) MUFFINN: cancer gene discovery via network analysis of somatic mutation
data, Genome Biology, 17.
da Rocha, E.L., et al. (2016) NetDecoder: a network biology platform that decodes context-specific
biological networks and gene activities, Nucleic Acids Research, 44, e100.
Dasika, M.S., Burgard, A. and Maranas, C.D. (2006) A computational framework for the topological
analysis and targeted disruption of signal transduction networks, Biophysical Journal, 91, 382-398.
Davis, P.M., Cynthia G, et al. (2009) Comparative Toxicogenomics Database: a knowledgebase and
discovery tool for chemical-gene-disease networks, Nucleic Acids Research, 37, D786.
Eke, I. and Cordes, N. (2015) Focal adhesion signaling and therapy resistance in cancer, Seminars in
Cancer Biology, 31, 65-75.
Farrow, J.M., Yang, J.C. and Evans, C.P. (2014) Autophagy as a modulator and target in prostate
cancer, Nature Reviews Urology, 11, 508-516.
Frolkis, A., et al. (2009) SMPDB: The Small Molecule Pathway Database, Nucleic Acids Research, 38,
D480-D487.
Goh, K.I., et al. (2007) The human disease network, Proceedings of the National Academy of Sciences
of the United States of America, 104, 8685-8690.
Huang, J., et al. (2011) eResponseNet: a package prioritizing candidate disease genes through cellular
pathways, Bioinformatics, 27, 2319-2320.
Iwata, H., et al. (2015) Systematic drug repositioning for a wide range of diseases with integrative
analyses of phenotypic and molecular data, Journal of Chemical Information and Modeling, 55, 44630

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

459.
Iwata, H., et al. (2015) Systematic Drug Repositioning for a Wide Range of Diseases with Integrative
Analyses of Phenotypic and Molecular Data, Journal of Chemical Information and Modeling, 55, 446459.
Jewison, T., et al. (2014) SMPDB 2.0: Big Improvements to the Small Molecule Pathway Database,
Nucleic Acids Research, 42, 478-484.
Kaapu, K.J., et al. (2015) Sotalol, but not digoxin is associated with decreased prostate cancer risk: A
population-based case-control study, International Journal of Cancer, 137, 1187-1195.
Kahn, B.B. and Flier, J.S. (2000) Obesity and insulin resistance, The Journal of Clinical Investigation,
106, 473-481.
Kutalik, Z., Beckmann, J. and Bergmann, S. (2008) A modular approach for integrative analysis of
large-scale gene-expression and drug-response data, Nature Biotechnology., 26, 531.
Langin, D., et al. (2005) Adipocyte lipases and defect of lipolysis in human obesity, Diabetes, 54,
3190-3197.
Lathia, J.D., Mattson, M.P. and Cheng, A. (2008) Notch: from neural development to neurological
disorders, Journal of Neurochemistry, 107, 1471-1481.
Lu, L. and Yu, H. (2018) DR2DI: a powerful computational tool for predicting novel drug-disease
associations, Journal of Computer-Aided Molecular Design, 32, 633-642.
Moretto, E., et al. (2018) Glutamatergic synapses in neurodevelopmental disorders, Progress in
Neuropsychopharmacology & Biological Psychiatry, 84, 328-342.
Neschadim, A., Summerlee, A.J. and Silvertown, J.D. (2015) Targeting the relaxin hormonal pathway
in prostate cancer, International Journal of Cancer, 137, 2287-2295.
Ogretmen, B. (2018) Sphingolipid metabolism in cancer signalling and therapy, Nature Reviews
Cancer, 18, 33-50.
Olsson, U., et al. (2001) Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic
cells may contribute to dyslipidemia of insulin resistance, Diabetes, 50, 2126-2132.
Ozvegy-Laczka, C., et al. (2005) Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug
transporters, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer
chemotherapy, 8, 15-26.
Paul, S.M., et al. (2010) How to improve R&D productivity: the pharmaceutical industry's grand
challenge, Nature Review Drug Discovery, 9, 203-214.
Pi√±ero, J., et al. (2016) DisGeNET: a comprehensive platform integrating information on human
disease-associated genes and variants, Nucleic Acids Research, 45, D833-D839.
Tata, A.M., et al. (2014) Cholinergic system dysfunction and neurodegenerative diseases: cause or
effect?, CNS & neurological disorders drug targets, 13, 1294-1303.
Taylor, V.H. and Macqueen, G.M. (2010) The Role of Adipokines in Understanding the Associations
31

bioRxiv preprint doi: https://doi.org/10.1101/749762; this version posted August 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

between Obesity and Depression, Journal of Obesity, 2010.
Viollet, B., et al. (2009) Targeting the AMPK pathway for the treatment of Type 2 diabetes, Frontiers
in Bioscience, 14, 3380-3400.
von Eichborn, J., et al. (2011) PROMISCUOUS: a database for network-based drug-repositioning,
Nucleic Acids Research, 39, D1060-D1066.
Wang, L., et al. (2014) Systematic analysis of new drug indications by drug-gene-disease coherent
subnetworks, CPT Pharmacometrics System Pharmacology, 3, e146
Yeger-Lotem, E., et al. (2009) Bridging the gap between high-throughput genetic and transcriptional
data reveals cellular pathways responding to alpha-synuclein toxicity, Nature Genetics, 41, 316.
Yildirim, M.A., et al. (2007) Drug-target network, Nature. Biotechnology., 25, 1119-1126.
You, J., et al. (2018) RNA-Seq analysis and comparison of corneal epithelium in keratoconus and
myopia patients, Scientific Reports, 8, 389.
Yu, G., et al. (2012) clusterProfiler: an R package for comparing biological themes among gene
clusters, Omics: A Journal of Integrative Biology, 16, 284-287.
Yu, H., Chen, X. and Lu, L. (2017) Large-scale prediction of microRNA-disease associations by
combinatorial prioritization algorithm, Scientific Report, 7, 43792.
Zhao, S. and Li, S. (2012) A co-module approach for elucidating drug‚Äìdisease associations and
revealing their molecular basis, Bioinformatics, 28, 955-961.

32

